| abstract |
The present technology relates generally to compositions and methods for preventing or treating diseases associated with mutant leptin receptors, leptin deficiency or leptin disorders. The technology also relates to administering an effective amount of an anti-leptin receptor antibody to treat a subject suffering from or predisposed to a disease associated with a mutant leptin receptor, obesity, leptin deficiency, leptin resistance, and/or hypoleptinemia. will be. |